Because of the inaccuracy and low efficiencies of traditional treatment, such as surgery, chemotherapy, and radiotherapy, in recent years, RDC (Radionuclide Drug Conjugate), with targeted diagnosis and imaging, has been widely noticed and studied in recent years. The targeting biomolecules in RDC could be antibodies, small molecules, and peptides, in which antibodies are most commonly used, also name RAC (Radionuclide Antibody Conjugate). Learn more: rdc tumor specific antigen

The Chelator in RDC (Radionuclide Drug Conjugate) is used to link the radionuclide and the targeting molecule in order to integrate the targeting and effectiveness of RDC. A number of chelators are now applied in the conjugation process.

Rdcthera offers chelators screening and synthesis services, for lateral chelator conjugation services, including covalently binding antibodies, small molecules, and peptides to metal ions.

Learn more: chelators hbed

RDC (Radionuclide Drug Conjugate) is a newly discovered concept for clinical cancer diagnosis and treatment. The tumor cell is a classic in vitro model for preclinical investigations.

Rdcthera has established multiple tumor cell lines and organ models for tumor inhibition potency analysis. Learn more：Tumor Inhibition Potency